Harmony Biosciences/$HRMY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Ticker
$HRMY
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
268
ISIN
US4131971040
Website
HRMY Metrics
BasicAdvanced
$2B
13.08
$2.62
0.82
-
Price and volume
Market cap
$2B
Beta
0.82
52-week high
$40.93
52-week low
$26.47
Average daily volume
646K
Financial strength
Current ratio
3.67
Quick ratio
3.5
Long term debt to equity
22.042
Total debt to equity
24.63
Interest coverage (TTM)
11.61%
Profitability
EBITDA (TTM)
218.994
Gross margin (TTM)
78.34%
Net profit margin (TTM)
20.50%
Operating margin (TTM)
26.18%
Effective tax rate (TTM)
22.55%
Revenue per employee (TTM)
$2,780,000
Management effectiveness
Return on assets (TTM)
12.81%
Return on equity (TTM)
24.71%
Valuation
Price to earnings (TTM)
13.08
Price to revenue (TTM)
2.625
Price to book
2.73
Price to tangible book (TTM)
3.21
Price to free cash flow (TTM)
10.032
Free cash flow yield (TTM)
9.97%
Free cash flow per share (TTM)
341.79%
Growth
Revenue change (TTM)
20.62%
Earnings per share change (TTM)
13.13%
3-year revenue growth (CAGR)
31.03%
3-year earnings per share growth (CAGR)
48.35%
What the Analysts think about HRMY
Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.
Bulls say / Bears say
Harmony Biosciences reported a 29% increase in net sales for WAKIX, totaling $172.8 million in Q2 2024, indicating strong product performance. (Investing.com)
The company maintains its 2025 net revenue guidance of $820-$860 million, reflecting confidence in its long-term strategy. (Investing.com)
Harmony Biosciences is advancing its high-dose pitolisant program, aiming to meet unmet medical needs in the narcolepsy community. (Investing.com)
The FDA issued a Refusal to File letter for Harmony's submission of pitolisant for treating idiopathic hypersomnia, delaying expansion plans. (Investing.com)
Harmony faces patent challenges from Novugen Pharma and Lupin Ltd., threatening the exclusivity of its product Wakix. (Markets Insider)
Analysts have expressed concerns over slowing patient growth and unchanged revenue guidance, leading to a maintained Sell rating. (Markets Insider)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
HRMY Financial Performance
Revenues and expenses
HRMY Earnings Performance
Company profitability
HRMY News
AllArticlesVideos
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
Business Wire·4 weeks ago
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
Business Wire·1 month ago
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harmony Biosciences stock?
Harmony Biosciences (HRMY) has a market cap of $2B as of July 10, 2025.
What is the P/E ratio for Harmony Biosciences stock?
The price to earnings (P/E) ratio for Harmony Biosciences (HRMY) stock is 13.08 as of July 10, 2025.
Does Harmony Biosciences stock pay dividends?
No, Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Harmony Biosciences dividend payment date?
Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders.
What is the beta indicator for Harmony Biosciences?
Harmony Biosciences (HRMY) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.